Kevin Conroy

Telehealth

Exact Sciences Highlights The Opportunity To Seek Screening With Cologuard® Through Telehealth | Markets Insider | Business Insider | 4/2/2020

telehealth provider. During the COVID-19 pandemic, people are staying home to avoid spreading the virus. Telehealth offers a way to screen more people at home, even during a public health crisis. “Cancer doesn’t stop for anything. As the country faces a pandemic, we are letting people know they can request Cologuard online from a health care provider, without an office visit,” said Kevin Conroy , Exact Sciences chairman and CEO …

Follow Kevin Conroy:    

Exact Sciences

Exact Sciences Highlights The Opportunity To Seek Screening With Cologuard® Through Telehealth | Markets Insider | Business Insider | 4/2/2020

MADISON, Wis. , April 2, 2020 /PRNewswire/ – Exact Sciences Corp. (NASDAQ: EXAS) today announced it would be devoting significant patient education resources toward the ability to request Cologuard® online through a telehealth provider. During the COVID … from a health care provider, without an office visit,” said Kevin Conroy , Exact Sciences chairman and CEO. “While Americans are at home trying to prevent the spread of COVID-19 in their communities, they can …

COVID-19

Exact Sciences Highlights The Opportunity To Seek Screening With Cologuard® Through Telehealth | Markets Insider | Business Insider | 4/2/2020

COVID-19 pandemic, people are staying home to avoid spreading the virus. Telehealth offers a way to screen more people at home, even during a public health crisis. “Cancer doesn’t stop for anything. As the country faces a pandemic, we are letting people know they can request Cologuard online from a health care provider, without an office visit,” said Kevin Conroy , Exact Sciences chairman and CEO. “While Americans are at …

Pfizer

Exact Sciences tees up annual Cologuard golf match with pros, patients and celebrities | FiercePharma | 3/4/2020

Pfizer marketing tie-up Kevin Conroy, CEO of Exact Sciences, said the partnership has proven effective, noting that the televised tournament reliably results in specific Google search spikes for the test. “One of the hard things about screening is that it’s focused on people who are healthy. We live in a world where people go to the doctor when they’re sick. This is about taking control of your own health …

Mayo Clinic

Exact Sciences tees up annual Cologuard golf match with pros, patients and celebrities | FiercePharma | 3/4/2020

… than two million to be sold in 2020. RELATED: Exact Sciences starts to see payoff from Pfizer marketing tie-up Kevin Conroy, CEO of Exact Sciences, said the partnership has proven effective, noting that the … cancer patients and survivors were in attendance. RELATED: Exact Sciences, Mayo Clinic launch 150,000-strong Cologuard study Exact Sciences began sponsoring the tour in 2017 after Conroy and Kelly met while traveling on an airplane …

Oncotype

Exact Sciences Announces Fourth-Quarter 2019 Results | PR Newswire | 2/11/2020

Kevin Conroy , chairman and CEO of Exact Sciences. “The strong foundation we’ve built for Cologuard and Oncotype DX and the capabilities of our combined team position us well to continue to grow our core business and deliver more innovative cancer tests to people in need.” Fourth-Quarter 2019 Financial Results For the three-month period ended December 31, 2019 , as compared to the same period of 2018 (where applicable): Total …

Medicare

Dr. David Ahlquist, co-inventor of Cologuard, named a Fellow of the National Academy of Inventors | PR Newswire | 12/4/2019

… years ago, Dr. Ahlquist and the Mayo Clinic team focused on the power of cancer screening and early detection,” said Kevin Conroy , chairman and CEO of Exact Sciences. “Dr. Ahlquist’s vision led the way in … of people with cancer received a negative result (false negative). Medicare and most major insurers cover Cologuard. For more information about Cologuard, visit www.cologuardtest.com . Rx Only. Forward-Looking Statements This news release contains forward-looking …

Cancer Diagnostics

Is Exact Sciences Stock a Buy? | 11/19/2019

… This month, Exact Sciences ( NASDAQ:EXAS ) finalized its purchase of Genomic Health, creating a formidable player in the realm of cancer diagnostics. Exact shelled out approximately $1.06 billion in cash and issued roughly 17.4 million … test. On its third-quarter conference call, Chairman and CEO Kevin Conroy spelled out its goal for Cologuard to “capture at least 40% of the U.S. colorectal screening market,” a significant increase from the current …

Diagnostic Tests

WisBusiness: Exact Sciences liver cancer test granted breakthrough device designation | 11/13/2019

Kevin Conroy says recently published study results show an improvement over other diagnostic tests. A release from the company shows more than 42,000 Americans and 780,000 people around the world are diagnosed with liver cancer each year, with HCC accounting for about 90 percent of cases. “There is a significant, worldwide unmet need for a blood-based, early detection diagnostic test for liver cancer in persons with elevated risk for …

Genomic Health

Exact Sciences completes acquisition of Genomic Health for $2.8bn | 11/11/2019

Molecular diagnostics firm Exact Sciences has closed its approximately $2.8bn acquisition of genomic diagnostics maker Genomic Health. In July, Exact Sciences signed a definitive agreement to acquire genomic diagnostics maker Genomic Health in a cash-and-stock deal. Exact Sciences chairman and CEO Kevin Conroy said: “We’re excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver advanced tests to providers and patients along …

Molecular Diagnostics

Exact Sciences completes acquisition of Genomic Health for $2.8bn | 11/11/2019

Molecular diagnostics firm Exact Sciences has closed its approximately $2.8bn acquisition of genomic diagnostics maker Genomic Health. In July, Exact Sciences signed a definitive agreement to acquire genomic diagnostics maker Genomic Health in a cash-and-stock deal. Exact Sciences chairman and CEO Kevin Conroy said: “We’re excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver advanced tests to providers and patients along …

Food and Drug Administration

Exact Sciences Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation – Company Announcement - FT.com | Financial Times | 11/8/2019

… for patient care and ongoing research. Exact Sciences’ HCC test has also been granted Breakthrough Device designation by the U.S. Food and Drug Administration . The agency’s Breakthrough Devices program expedites development, assessment, and review processes … the world are considered high risk for developing HCC,” said Kevin Conroy , chairman and CEO of Exact Sciences . “A more sensitive and convenient blood-based test could help catch the disease earlier, which may lead …

National Committee for Quality Assurance

Exact Sciences Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation | PR Newswire | 11/8/2019

… to current guidelines v . “A growing number of patients around the world are considered high risk for developing HCC,” said Kevin Conroy , chairman and CEO of Exact Sciences. “A more sensitive and convenient blood-based … Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our ability to …

Clinical Research

Exact Sciences Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation – Company Announcement - FT.com | Financial Times | 11/8/2019

… test, which demonstrated 45% sensitivity at 90% specificity for early stage HCC. Lead author Naga Chalasani, M.D., Associate Dean for Clinical Research at Indiana University School of Medicine and Director, Division of Gastroenterology and Hepatology … the world are considered high risk for developing HCC,” said Kevin Conroy , chairman and CEO of Exact Sciences . “A more sensitive and convenient blood-based test could help catch the disease earlier, which may lead …

Indiana University School of Medicine

Exact Sciences Presents Data On Blood-Based Test For Detection Of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation – Company Announcement - FT.com | Financial Times | 11/8/2019

… 45% sensitivity at 90% specificity for early stage HCC. Lead author Naga Chalasani, M.D., Associate Dean for Clinical Research at Indiana University School of Medicine and Director, Division of Gastroenterology and Hepatology , will present the … the world are considered high risk for developing HCC,” said Kevin Conroy , chairman and CEO of Exact Sciences . “A more sensitive and convenient blood-based test could help catch the disease earlier, which may lead …

William Blair

Exact Sciences Corp (EXAS) Q3 2019 Earnings Call Transcript | The Motley Fool | 10/30/2019

… thanks, all of you for joining us for Exact Sciences’ third quarter 2019 conference call. On the call today are Kevin Conroy, the company’s Chairman and CEO; Jeff Elliott, our Chief Financial Officer; and Mark … first question comes from the line of Brian Weinstein with William Blair. Brian Weinstein – William Blair & Company L.L.C. – Analyst Hey, guys. Thanks for taking the questions. Wanted to start out just on a broad question …

Aetna

Exact Sciences Corp (EXAS) Q3 2019 Earnings Call Transcript | The Motley Fool | 10/30/2019

… thanks, all of you for joining us for Exact Sciences’ third quarter 2019 conference call. On the call today are Kevin Conroy, the company’s Chairman and CEO; Jeff Elliott, our Chief Financial Officer; and Mark … following the American Cancer Society guidelines update last year, including Aetna, CareFirst and Blue Shield of California. This is encouraging progress and our team is engaging with other payers educating their sales force and developing …

Goldman Sachs

Inside Genomic Health’s $2.8B deal: A false start, rejections and a mysterious last-minute party | The Business Journals | 10/5/2019

… enough to become a sticking point in the negotiations, even as Genomic Health CEO Kim Popovits and Exact Sciences CEO Kevin Conroy largely found agreement on the overarching price. Genomic Health’s board on June 13 … starting in October 2017 by Genomic Health’s longtime investment banker, Goldman Sachs & Co. LLC, about their interest in buying the company. The process resulted in two interested parties — one with a price range of $32 …

Leerink Partners

3 Strong Buy Mid-Cap Stocks with High Upside | Yahoo News | 9/26/2019

Kevin Conroy said, “We are giving health care providers a sensitive, noninvasive option that has the potential to help combat the rise of colorectal cancer rates among this younger group of people.” Leerink Partners analyst Puneet Souda noted of the move, “With an additional 19M patients to their overall population, EXAS is adding a $3B market opportunity, according to previous management commentary, which we believe offers additional upside to their …

Biotech

Exact Sciences to buy Genomic Health in $2.8B deal | FierceBiotech | 7/29/2019

… sales and expand adoption of Cologuard at a rapid pace, and Genomic Health’s Oncotype DX is the global standard of care to inform treatment decisions for women with breast cancer,” Exact Sciences CEO Kevin Conroy said in a statement . “Together, with our collective resources and broader platform, we will be able to provide our existing tests to more people, while also accelerating the development and launch of future cancer diagnostic …